Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kiora Pharmaceuticals, Inc. (KPRX : NSDQ)

• Company Description    Kiora Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company. It involved in developing and commercializing products for treating ophthalmic diseases. The company's product pipeline includes KIO-301, KIO-101 and KIO-201. Kiora Pharmaceuticals Inc., formerly known as EyeGate Pharmaceuticals Inc., is based in SALT LAKE CITY. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $3.01 Daily Weekly Monthly 20 Day Moving Average: 54,409 shares Shares Outstanding: 3.04 (millions) Market Capitalization: $9.16 (millions) Beta: -0.66 52 Week High: $4.86 52 Week Low: $2.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.27% -5.93% 12 Week 7.89% -9.25% Year To Date -8.79% -14.58%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 169 SAXONY RD. SUITE 212 - ENCINITAS,CA 92024 USA ph: 858-224-9600 fax: - investors@kiorapharma.com http://www.kiorapharma.com

• General Corporate Information    Officers Brian M. Strem - President and Chief Executive Officer Melissa Tosca - Chief Financial Officer Praveen Tyle - Director Lisa Walters-Hoffert - Director David Hollander - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 49721T507 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 3.04 Most Recent Split Date: 6.00 (0.11:1) Beta: -0.66 Market Capitalization: $9.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.39 Price/Cash Flow: 2.43 Price / Sales: - EPS Growth vs. Year Ago Period: -115.20% vs. Previous Quarter: 50.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -99.88% ROE 06/30/25 - - 03/31/25 - -42.82 12/31/24 - 11.61 ROA 06/30/25 - - 03/31/25 - -32.18 12/31/24 - 9.08 Current Ratio 06/30/25 - - 03/31/25 - 5.14 12/31/24 - 4.94 Quick Ratio 06/30/25 - - 03/31/25 - 5.14 12/31/24 - 4.94 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -49,315.00 12/31/24 - 35.33 Book Value 06/30/25 - - 03/31/25 - 7.79 12/31/24 - 8.58 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©